Moderate to severe diabetic retinopathy (DR) patients are a step closer to gaining an FDA indication for anti-VEGF Eylea (aflibercept, Regeneron) therapy as the drug’s manufacturer announces its Phase III trial results. The study shows that 80% of patients who were given an injection every eight weeks showed an improvement of two steps or more from baseline in diabetic retinopathy severity score (DRSS). Only 15% of a control group improved that much. Another group was given the injection once every 16 weeks and 65% of them showed similar improvement.

The company adds that the injections also lowered vision-threatening complications by 82% to 85% and the development of center-involved diabetic macular edema by 68% to 74% compared with sham injection.

Eylea is already approved for a number of patients, including age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and DR in patients with diabetic macular edema.

Kwok D. Eylea (aflibercept) injection improves diabetic retinopathy and reduces vision-threatening complications in phase 3 trial. Regeneron. Published October 25, 2018. Accessed October 26, 2018.